Merus stock had its Relative Strength (RS) Rating upgraded from 78 to 94 Thursday.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's unique RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks matches up against all other stocks in our database.
Decades of market research reveals that the market's biggest winners tend to have an RS Rating of above 80 as they launch their largest price moves.
Looking For Winning Stocks? Try This Simple Routine
Is Merus Stock A Buy?
Merus stock retook its 200-day moving average and is not currently offering a proper buying opportunity. See if the stock goes on to form a sound pattern that could spark a new run. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech company showed -53% earnings growth last quarter. Sales rose 40%. Keep an eye out for the company's next round of numbers on or around Aug. 5.
Merus stock earns the No. 41 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharmaceutcls, Dynavax Technologies and Vertex Pharmaceuticals are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
